Fármacos utilizados no tratamento do COVID-19 em pediatria

revisão integrativa

Autores

  • Kennedy Ferreira Bonifacio Hospital Materno Infantil de Brasília
  • Sarah Kelly Souza de Carvalho Faria Hospital Materno Infantil de Brasília
  • Alcidésio Sales de Souza Júnior Hospital Materno Infantil de Brasília

Palavras-chave:

SARS-CoV-2, 2019-nCOV, COVID-19, Pediatrics

Resumo

Foi realizada uma revisão bibliográfica integrativa sobre estudos recentemente publicados entre o período de 1º de Janeiro e 24 de Abril de 2020, utilizando -se as palavras-chave: 2019-nCOV; COVID-19; SARS-CoV-2 e pediatrics. Foram pesquisados os bancos de dados PubMed, Periódicos CAPES, Science Direct, Scielo, Biblioteca Virtual em Saúde e Lilacs. Um total de 10 artigos foram considerados elegíveis. Entre as principais classes terapêuticas citadas estavam os antivirais lopinavir/ritonavir, oseltamivir, o uso do interferon e de imunoglobulinas. Quase todos os tratamentos mencionados foram considerados potencialmente eficazes contra o COVID-19, no entanto ensaios clínicos são necessários para tal confirmação visto que há poucos estudos e que o uso dos medicamentos mencionados se encontra baseado no tratamento de outras doenças respiratórias.

Downloads

Não há dados estatísticos.

Biografia do Autor

Kennedy Ferreira Bonifacio, Hospital Materno Infantil de Brasília

Residente em Saúde da Criança - Escola Superior de Saúde (ESCS) – Secretaria de Estado de Saúde do Distrito Federal. Graduado em Farmácia  pela Universidade de Brasília (UnB).

Sarah Kelly Souza de Carvalho Faria, Hospital Materno Infantil de Brasília

Residente em Saúde da Criança- Escola Superior de Saúde (ESCS) – Secretaria de Estado de Saúde do Distrito Federal. Graduada em Farmácia  pela Universidade de Brasília (UnB).

Alcidésio Sales de Souza Júnior, Hospital Materno Infantil de Brasília

3Doutor em Desenvolvimento Inovação Tecnológica em Medicamentos pela Universidade Federal do Ceará/UFRN/UFRPE/UFPB, Preceptor do Programa de Residência Multiprofissional em Saúde da Criança, Hospital Materno Infantil de Brasília

Referências

Tezer H, Demirdağ T. Novel coronavirus disease (COVID-19) in children. Turkish Journal of Medical Sciences. 2020; 50: 592-603. https://doi.org/10.3906/sag-2004-174

Rothan H, Byrareddy S. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020; 109: 102433. https://doi.org/10.1016/j.jaut.2020.102433

Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. American Journal of Physiology-Endocrinology and Metabolism. 2020; 318 (5): 736-741.

Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. Morbidity and Mortality Weekly Report, v.69, n. 14, 2020.

Brasil. Ministério Da Saúde. Coronavírus/Brasil. Painel Coronavírus. Disponível em: <https://covid.saude.gov.br/>. Acesso em 30 abr. 2020.

Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico. COE Nº 11, Abr. 2020. Disponível em: https://www.saude.gov.br/images/pdf/2020/April/18/2020-04-17---BE11---Boletim-do-COE-21h.pdf .

Li Y, Guo F, Cao Y, Li L, Guo Y. Insight into COVID‐2019 for pediatricians. Pediatric Pulmonology. 2020; 55 (5).

Vaduganathan M, Vardeny O, Michel T, McMurray J, Pfeffer M, Solomon S. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653-1659. https://doi.org/10.1056/NEJMsr2005760.

Yonker L, Shen K. Lessons unfolding from pediatric cases of COVID‐19 disease caused by SARS‐CoV‐2 infection. Pediatric Pulmonary. 2020; 55 (5): 1085-1086. https://doi.org/10.1002/ppul.24748

Calvo C, López-Hortelano M, Vicente J, Martínez J. Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group. Anales de Pediatría (English Edition). 2020.

Li Y, Guo F, Cao Y, Li L, Guo Y. Insight into COVID‐2019 for pediatricians. Pediatric Pulmonology. 2020;55(5).

Chiotos K, Hayes M, Kimberlin D, Jones S, James S, Pinninti S et al. Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal of the Pediatric Infectious Diseases Society. 2020.

Sun D, Li H, Lu X, Xiao H, Ren J, Zhang F et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World Journal of Pediatrics. 2020. https://doi.org/10.1007/s12519-020-00354-4

Lu Q, Shi Y. Coronavirus disease (COVID‐19) and neonate: What neonatologist need to know. Journal of Medical Virology. 2020; 92 (6):564-567.

Chen Z, Fu J, Shu Q, Chen Y, Hua C, Li F et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World Journal of Pediatrics. 2020.

Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World Journal of Pediatrics. 2020. https://doi.org/10.1007/s12519-020-00343-7

Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19. The Pediatric Infectious Disease Journal. 2020;39 (5): 355-368. https://doi.org/ 10.1097/INF.0000000000002660

Rahimzadeh G, Ekrami Noghabi M, Kadkhodaei Elyaderani F, Navaeifar M, Enayati A, Manafi Anari A et al. COVID-19 Infection in Iranian Children: A Case Series of 9 Patients. Journal of Pediatrics Review. 2020:139-144.

Shen K, Yang Y. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World Journal of Pediatrics. 2020. https://doi.org/10.1007/s12519-020-00344-6

Devaux C, Rolain J, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. International Journal of Antimicrobial Agents. 2020; 105938.

Merino Argumánez C, Sáez de La Fuente I, Molina Collado Z, Suárez Pita D, Mestre Gómez B, Sanchez Izquierdo JA. La hidroxicloroquina, un fármaco potencialmente letal. Med Intensiva. 2017; 41: 257-259.

Poetker D, Reh D. A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids. Otolaryngologic Clinics of North America. 2010;43(4):753-768. https://doi.org/10.1016/j.otc.2010.04.003

Kapoor A, Pandurangi U, Arora V, Gupta A, Jaswal A, Nabar A et al. Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society. Indian Pacing and Electrophysiology Journal. 2020.

Jin Y, Cai L, Cheng Z, Cheng H, Deng T, Fan Y et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Medical Research. 2020;7(1).

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine. 2020.

Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 – an internet-based cross-sectional survey. Eurosurveillance. 2009; 14 (30).

Tullu MS. Oseltamivir. Journal of Postgraduate Medicine. 2009; 55 (3): 225-230. 10.4103/0022-3859.57411

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine. 2020.

Khalili J, Zhu H, Mak N, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. Journal of Medical Virology. 2020.

Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study. Clinical Microbiology and Infection. 2020.

Chandwani, A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Therapeutics and Clinical Risk Management. 2008; Volume 4: 1023-1033.

Arquivos adicionais

Publicado

2020-06-01

Como Citar

Bonifacio, K. F., Sarah Kelly Souza de Carvalho Faria, & Júnior, A. S. de S. . (2020). Fármacos utilizados no tratamento do COVID-19 em pediatria : revisão integrativa. Comunicação Em Ciências Da Saúde, 31(Suppl 1), 94-104. Recuperado de http://www.escs.edu.br/revistaccs/index.php/comunicacaoemcienciasdasaude/article/view/682